Genomic abnormality associated with vaginal bleeding in women using the levonogestrel intrauterine system

• Grant number: 20/06932-6
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2020
• End date: October 31, 2022
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Principal Investigator: Cássia Raquel Teatin Juliato
• Grantee: Cássia Raquel Teatin Juliato
• Host Institution: Centro de Atenção Integral à Saúde da Mulher (CAISM). Hospital da Mulher Professor Doutor José Aristodemo Pinotti. Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• City of the host institution: Campinas
• Associated researchers: Flávia Rocha Torelli ; Ilza Maria Urbano Monteiro ; Luis Guillermo Bahamondes

Abstract

Vaginal bleeding is the main reason for discontinuation in women using levonogestrel-releasing intrauterine system (IUD-LNG). Currently, there is no test able to predict which woman would have an unsatisfactory menstrual pattern. Objective: To evaluate the gene expression profile of women who use IUD-LNG with or without abnormal vaginal bleeding during the first year of usage. Methods: One hundred women from the Family Planning clinic of CAISM/UNICAMP who have chosen the IUD-LNG as a contraceptive method will be included. These women will be submitted to an endometrial biopsy immediately before the placement of the IUD-LNG and also will be under a bleeding pattern assessment for 1 year. After 12 months, gene expression associated with inflammation genes (FKBP51, NR3C1, ADAMTS1, ADH1A, CLEC3B, VEGF, CYP3A4, NR1I2, NPTX1, SERPINE1, STC1) will be evaluated among women who have had normal bleeding, abnormal bleeding as well as non-bleeding ones. For statistical analysis, either Ç2 test or Fisher's exact test will be used in order to check the difference between endometrial gene expression. (AU)